Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of CCX507-H in healthy volunteers
NL-OMON36896Phase 1Active, not recruiting
- Sponsor
- ChemoCentryx
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CCX507-H in Crohn's disease and inflammatory bowel disease (IBD) (10 cohorts), sponsored by ChemoCentryx. Primary endpoints: Safety and tolerability, Pharmacodynamics and 2 more. Started Nov 2012; status: active, not recruiting.
02
Drugs
CCX507-H
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON36896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36896.